Drugs

New Guidance on Adaptive Clinical Trial Designs

FDA has posted an International Council for Harmonization draft guideline entitled E20 Adaptive Designs for Clinical Trials that provides recommendations on using adaptive designs in confirmatory clinical trials. The guideline lays out principles to help sponsors ensure that such trials produce reliable and interpretable evidence to support benefit-risk assessments of new treatments.

Adaptive designs allow pre-specified modifications to a trial — such as sample size adjustments or dose selection — based on interim analyses of data already collected, the document says. Such flexibility can improve efficiency, reduce patient exposure to ineffective treatments, and enhance understanding of treatment effects, it says. However, the agency cautions that adaptive designs also carry risks, including added complexity, potential biases in results, and challenges in maintaining trial integrity.

The guidance stresses that adaptations must be planned in advance, with clear justification and safeguards. Sponsors are expected to carefully weigh the advantages against risks such as increased Type I error probability, biased treatment effect estimates, and reduced safety data. The document also emphasizes the need for rigorous planning, appropriate statistical methods, and strong oversight, often through independent data monitoring committees to protect trial validity.

Key principles outlined in the guideline include ensuring that adaptive designs fit within the overall drug development program, maintaining adequate planning and documentation, limiting the chances of false positive or false negative conclusions, ensuring reliable estimation of treatment effects, and safeguarding trial integrity. FDA notes that sponsors should be prepared to discuss adaptation strategies with regulators early in trial planning.

While the guideline primarily addresses confirmatory clinical trials, FDA says many of the principles are relevant across all phases of clinical development.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome